Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Pharmacokinetic rationale for the rivastigmine patch.

Cummings J, Lefèvre G, Small G, Appel-Dingemanse S.

Neurology. 2007 Jul 24;69(4 Suppl 1):S10-3. Review.

PMID:
17646618
2.

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

Kurz A, Farlow M, Lefèvre G.

Int J Clin Pract. 2009 May;63(5):799-805. doi: 10.1111/j.1742-1241.2009.02052.x. Review.

3.

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.

Winblad B, Machado JC.

Expert Opin Drug Deliv. 2008 Dec;5(12):1377-86. doi: 10.1517/17425240802542690 . Review.

PMID:
19040398
4.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

Darreh-Shori T, Jelic V.

Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717. Review.

PMID:
20021294
5.

Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.

Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniëls H, Dziadulewicz E, Förstl H, Frölich L, Gabryelewicz T, Levin O, Lindesay J, Martínez-Lage P, Monsch A, Tsolaki M, van Laar T.

CNS Neurosci Ther. 2010 Aug;16(4):246-53. doi: 10.1111/j.1755-5949.2010.00141.x. Epub 2010 Apr 16. Review.

PMID:
20370805
6.

Rivastigmine transdermal patch: role in the management of Alzheimer's disease.

Guay DR.

Consult Pharm. 2008 Aug;23(8):598-609. Review.

PMID:
19032006
7.

Rivastigmine in Parkinson's disease dementia.

Lalli S, Albanese A.

Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181. Review.

PMID:
18671661
8.

Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

Sadowsky C, Perez JA, Bouchard RW, Goodman I, Tekin S.

CNS Neurosci Ther. 2010 Spring;16(1):51-60. doi: 10.1111/j.1755-5949.2009.00119.x. Review.

PMID:
20070789
9.

A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.

Cummings J, Winblad B.

Expert Rev Neurother. 2007 Nov;7(11):1457-63. Review.

PMID:
17997695
10.

Rationale for transdermal drug administration in Alzheimer disease.

Oertel W, Ross JS, Eggert K, Adler G.

Neurology. 2007 Jul 24;69(4 Suppl 1):S4-9. Review.

PMID:
17646621
11.

A review of rivastigmine: a reversible cholinesterase inhibitor.

Williams BR, Nazarians A, Gill MA.

Clin Ther. 2003 Jun;25(6):1634-53. Review.

PMID:
12860489
13.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.

Grossberg GT, Sadowsky C, Olin JT.

Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19. Review.

PMID:
20102418
14.

Update on rivastigmine.

Farlow MR.

Neurologist. 2003 Sep;9(5):230-4. Review.

PMID:
14587496
15.

Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.

Greenspoon J, Herrmann N, Adam DN.

CNS Drugs. 2011 Jul;25(7):575-83. doi: 10.2165/11592230-000000000-00000. Review.

PMID:
21623641
16.

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.

Dhillon S.

Drugs. 2011 Jun 18;71(9):1209-31. doi: 10.2165/11206380-000000000-00000. Review.

PMID:
21711064
17.

Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.

Amanatkar HR, Grossberg GT.

Expert Rev Neurother. 2014 Oct;14(10):1119-25. doi: 10.1586/14737175.2014.955852. Epub 2014 Sep 9. Review.

PMID:
25201245
18.

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000. Review.

PMID:
22054233
20.

Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.

Frampton JE.

Drugs Aging. 2014 Aug;31(8):639-49. doi: 10.1007/s40266-014-0197-x. Review.

PMID:
24989628

Supplemental Content

Support Center